Puggina Anna, Marijam Alen, Cailloux Olivier, Vicentini Marta, Turriani Elisa, Verelst Frederik, Last Theo, Rieger Christina, Bonanni Paolo, de Waure Chiara, Marijic Pavo, Tervonen Tommi
GSK, Verona, Italy.
GSK, Wavre, Belgium.
PLoS One. 2025 Aug 28;20(8):e0330763. doi: 10.1371/journal.pone.0330763. eCollection 2025.
Respiratory syncytial virus (RSV) causes substantial morbidity and mortality among older adults and individuals with chronic diseases, putting pressure on healthcare systems. RSV vaccines became available in 2023, however, physicians' knowledge and attitudes regarding RSV and RSV vaccines may hinder uptake. We aimed to understand physicians' knowledge, attitudes, and perceptions of respiratory infections, including RSV, and vaccination. A pre-tested cross-sectional survey was fielded with physicians who commonly administer or recommend respiratory vaccines in Germany and Italy. Regression models assessed physicians' characteristics associated with knowledge and perceptions of RSV. Overall, 307 physicians (Germany: n = 152; Italy: n = 155) completed the survey. Physicians had good mean RSV disease knowledge scores (Germany: 3.8/5; Italy: 3.3/5). Most (Germany: 68%; Italy: 72%) indicated wanting further information on RSV, versus <35% for other respiratory diseases. Most considered RSV an important burden, especially for adults aged ≥50 years with immunocompromising conditions (Germany: >96%; Italy: >92%) and ≥60 years with chronic conditions (Germany: >95%; Italy: >87%). Physicians seeing >100 versus ≤100 patients weekly, and general practitioners versus other specialists, perceived RSV burden as more important. Perceived barriers to RSV vaccination included lack of national recommendation and reimbursement (Germany: 92%; Italy: 89%), and patients not being informed on getting vaccinated (Germany: 71%; Italy: 59%). In conclusion, physicians generally considered RSV an important pathogen for older adults and those with chronic conditions at risk of severe infection. Most wanted more information on RSV, thus medical education is important to address knowledge gaps and enable physicians to guide patients in making informed vaccination decisions.
呼吸道合胞病毒(RSV)在老年人和患有慢性疾病的个体中会导致大量发病和死亡,给医疗系统带来压力。2023年呼吸道合胞病毒疫苗上市,然而,医生对呼吸道合胞病毒及相关疫苗的了解和态度可能会阻碍疫苗的接种。我们旨在了解医生对包括呼吸道合胞病毒在内的呼吸道感染及疫苗接种的知识、态度和看法。我们对德国和意大利通常接种或推荐呼吸道疫苗的医生进行了一项经过预测试的横断面调查。回归模型评估了与医生对呼吸道合胞病毒的知识和看法相关的特征。总体而言,307名医生(德国:n = 152;意大利:n = 155)完成了调查。医生对呼吸道合胞病毒疾病的平均知识得分较高(德国:3.8/5;意大利:3.3/5)。大多数医生(德国:68%;意大利:72%)表示希望获得更多关于呼吸道合胞病毒的信息,而对其他呼吸道疾病表示希望获得更多信息的医生比例不到35%。大多数医生认为呼吸道合胞病毒是一个重要负担,特别是对于年龄≥50岁且有免疫功能低下状况的成年人(德国:>96%;意大利:>92%)以及年龄≥60岁且患有慢性疾病的成年人(德国:>95%;意大利:>87%)。每周看诊超过100名患者的医生与每周看诊≤100名患者的医生相比,以及全科医生与其他专科医生相比,认为呼吸道合胞病毒负担更为重要。呼吸道合胞病毒疫苗接种的感知障碍包括缺乏国家推荐和报销(德国:92%;意大利:89%),以及患者未被告知接种疫苗(德国:71%;意大利:59%)。总之,医生普遍认为呼吸道合胞病毒是老年人和有严重感染风险的慢性疾病患者的重要病原体。大多数医生希望获得更多关于呼吸道合胞病毒的信息,因此医学教育对于填补知识空白以及使医生能够指导患者做出明智的疫苗接种决策非常重要。